Limited Evidence On Best Next Seizure Medicine

What was studied

This paper was a systematic review of randomized controlled trials about what to do after the first antiseizure medication (ASM) does not control focal epilepsy. It looked at two main strategies: adding a second medicine to the first one (add-on) or stopping the first and changing to a different medicine (switch).

The review included children and adults with focal epilepsy whose first ASM had failed for any reason. The authors found 6 trials, with 961 total participants, published from 1998 to 2012. These trials tested 7 different ASMs. The main outcomes were seizure remission and whether seizures were reduced by at least 50%.

What they found

The evidence was limited, and the studies were too different from each other to combine into one pooled analysis. Across the trials, short-term seizure remission at about 3 months ranged from 11% to 43% in add-on studies and 8% to 43% in switch studies. Rates of at least 50% seizure reduction ranged from 34% to 63% for add-on treatment and 38% to 76% for switching.

Only a few significant differences between medicines were found. In one add-on trial, valproate had a higher responder rate than primidone, and lamotrigine had a lower responder rate than valproate. In a switch strategy, lamotrigine had lower treatment failure rates than valproate and fewer adverse effects than carbamazepine and valproate. Overall, seizure outcomes were modest and were reported as comparable across treatment strategies.

Limits of the evidence

This review cannot show that one overall strategy is best after the first ASM fails. There were only 6 trials, most were judged to have high risk of bias, and they were published years ago. The studies differed in design, medicines used, and follow-up time, which makes comparisons harder.

Another important limit is that seizure remission was measured at a short-term endpoint of about 3 months, while treatment decisions may need longer follow-up. Because the evidence is sparse and outdated, the results may not fully reflect current practice or newer medicines.

For families and caregivers

For families, this review suggests that there is not strong, up-to-date trial evidence showing that adding a medicine is clearly better than switching, or the other way around, after the first medicine fails in focal epilepsy. The benefits seen in the studies were modest, and only a few medicine-to-medicine differences were reported.

This matters because treatment after a first medication failure is common, but the best next step may depend on seizure control, side effects, age, and other health factors. The study supports careful discussion with an epilepsy clinician, while also showing that better research is still needed.

What to watch next

Stronger evidence would likely require newer, longer studies that compare add-on versus switch strategies and include current antiseizure medicines.

Terms in this summary

focal epilepsy

Epilepsy in which seizures start in one part of the brain.

antiseizure medication (ASM)

A medicine used to prevent or reduce seizures.

add-on therapy

Adding another seizure medicine while continuing the current one.

switch strategy

Stopping one seizure medicine and changing to a different one.

seizure remission

A period of time with no seizures.

responder rate

The share of patients whose seizure frequency drops by at least 50%.

randomized controlled trial

A study in which people are assigned by chance to different treatments to compare results.

risk of bias

The chance that study methods may have affected the results in a misleading way.